NEW YORK (GenomeWeb) – Aegis Sciences has acquired molecular diagnostics firm Diagnovus for an undisclosed amount, the companies said today.
Diagnovus, based in Nashville, Tenn., has developed a suite of oncology and gastroenterology tests using a range of technologies, including PCR, next-generation sequencing, and gene expression analysis. In addition, it offers clinical trial, bioinformatics, and other clinical services on a variety of technology platforms.
Aegis, also based in Nashville, is a toxicology laboratory that specializes in forensic and healthcare services.
Aegis' Founder, Chairman, and CEO David Black said in a statement that the Diagnovus acquisition would enable Aegis to expand its healthcare laboratory testing services. "The delivery of patient-specific genetic information to physicians will improve management of disease and prescribing of necessary medication," Black said.
"Aegis' reputation and client base will allow us to offer our developed molecular diagnostic testing services to a much larger patient population," Diagnovus President and Co-founder James Stover said in a statement.